# Advisor Review - GPT-5-mini

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-01T10:03:29.636709
**Route:** OpenRouter + LaTeX
**Tokens:** 16005 in / 891 out
**Response SHA256:** 5057640317d68e1d

---

I checked the draft for fatal errors in the four specified categories (Data-Design Alignment, Regression Sanity, Completeness, Internal Consistency). I examined all tables, figures, and the reported sample periods, treatment timing, synthetic-control construction, placebo and robustness results.

Findings: I found ZERO fatal errors.

Notes (brief):
- Treatment timing (May 29, 2019 → 2019Q2) is consistent with the reported data coverage (2010Q1–2023Q4). Pre/post sample lengths (T0 = 37, n = 19) are consistent across text and tables.
- Synthetic-control implementation details (weights, NNLS, pre-treatment fit RMSE/R2) are internally consistent with reported summaries and with the quarterly gap table.
- Reported statistics conform to sanity checks: no R2 outside [0,1], no implausibly large standard errors or coefficients, no negative/NaN/NA placeholders, and sample sizes/observation counts are reported.
- Completeness: all required elements for the synthetic-control analysis are present (donor list, weights, pre/post windows, placebo tests, leave-one-out, COVID sensitivity). No "TBD"/"TODO"/"NA" placeholders in key tables.
- Internal consistency: numbers cited in text match tables (e.g., ATT = 4.52, pre-COVID ATT = 0.58), treatment timing and sample periods are used consistently across sections.

Recommendation: The paper appears free of the kinds of fatal empirical/design/reporting errors that would embarrass the author or waste referees' time. The substantive caveats you already discuss (COVID confounding, concentrated donor weights, limited pre-COVID post-treatment window, need for regional analysis) are appropriate and should remain.

ADVISOR VERDICT: PASS